-transparent.png){kind=logo}
The present study seeks to determine the extent to which a set of non-specific factors can stably predict response to either chlordiazepoxide (CDZ) or placebo (PBO) and the extent to which such prediction is specific to or distinctive for each treatment agent. For this purpose data were assembled for 447 primarily anxious neurotic outpatients treated with either CDZ or PBO in 4 week double blind drug trials performed over the past ten years and divided into two comparable subsamples for each treatment agent. A series of analyses revealed modest replicability but considerable drug specificity for a Global improvement measure. Replicability was considerable higher for a patient measure of Symptom Change, but its specificity to treatment agent was considerably less.
R W Downing, and
K Rickels
January 1972,
Current therapeutic research, clinical and experimental,
R W Downing, and
K Rickels
August 1972,
Diseases of the nervous system,
R W Downing, and
K Rickels
January 1987,
Neuropsychobiology,
R W Downing, and
K Rickels
September 1970,
Comprehensive psychiatry,
R W Downing, and
K Rickels
September 1972,
Current therapeutic research, clinical and experimental,
R W Downing, and
K Rickels
April 1970,
Current therapeutic research, clinical and experimental,
R W Downing, and
K Rickels
August 1967,
The Journal of nervous and mental disease,
R W Downing, and
K Rickels
January 1970,
Clinical pharmacology and therapeutics,
R W Downing, and
K Rickels
July 1972,
The Journal of clinical pharmacology and new drugs,
R W Downing, and
K Rickels
April 1968,
Multivariate behavioral research,
